KR20230093338A - 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물 - Google Patents

슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물 Download PDF

Info

Publication number
KR20230093338A
KR20230093338A KR1020237019235A KR20237019235A KR20230093338A KR 20230093338 A KR20230093338 A KR 20230093338A KR 1020237019235 A KR1020237019235 A KR 1020237019235A KR 20237019235 A KR20237019235 A KR 20237019235A KR 20230093338 A KR20230093338 A KR 20230093338A
Authority
KR
South Korea
Prior art keywords
seq
ser
val
thr
leu
Prior art date
Application number
KR1020237019235A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 웨이너
아미 파텔
지안 얀
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지
이노비오 파마수티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아, 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지, 이노비오 파마수티컬즈, 인크. filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20230093338A publication Critical patent/KR20230093338A/ko

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020237019235A 2016-05-05 2017-05-05 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물 KR20230093338A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662332363P 2016-05-05 2016-05-05
US62/332,363 2016-05-05
KR1020187035163A KR20190025826A (ko) 2016-05-05 2017-05-05 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물
PCT/US2017/031449 WO2017193101A1 (en) 2016-05-05 2017-05-05 Dna antibody constructs for use against pseudomonas aeruginosa

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035163A Division KR20190025826A (ko) 2016-05-05 2017-05-05 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물

Publications (1)

Publication Number Publication Date
KR20230093338A true KR20230093338A (ko) 2023-06-27

Family

ID=60203552

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187035163A KR20190025826A (ko) 2016-05-05 2017-05-05 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물
KR1020237019235A KR20230093338A (ko) 2016-05-05 2017-05-05 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020187035163A KR20190025826A (ko) 2016-05-05 2017-05-05 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물

Country Status (12)

Country Link
US (1) US20190153076A1 (ru)
EP (1) EP3452090A4 (ru)
JP (2) JP2019520085A (ru)
KR (2) KR20190025826A (ru)
CN (1) CN110072554A (ru)
AU (2) AU2017261374B2 (ru)
BR (1) BR112018072716A2 (ru)
CA (1) CA3023094A1 (ru)
EA (1) EA201892525A1 (ru)
MX (1) MX2018013525A (ru)
SG (2) SG10202011016WA (ru)
WO (1) WO2017193101A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6058645B2 (ja) 2011-06-10 2017-01-11 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用
CA2854817C (en) * 2011-11-07 2022-08-16 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
JP2021512600A (ja) * 2018-01-31 2021-05-20 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー 呼吸器合胞体ウイルスに対して使用するための核酸抗体構築物
US20220275065A1 (en) * 2019-07-31 2022-09-01 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
WO2021022107A1 (en) * 2019-07-31 2021-02-04 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
WO2021244421A1 (en) * 2020-06-01 2021-12-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing pseudomonas pcrv and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220117A2 (en) * 2007-11-30 2010-08-25 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
JP6058645B2 (ja) * 2011-06-10 2017-01-11 メディミューン,エルエルシー 抗シュードモナス属(Pseudomonas)Psl結合分子およびその使用
CN107586340B (zh) * 2011-08-23 2022-01-21 罗切格利卡特公司 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
JP2014526472A (ja) * 2011-09-08 2014-10-06 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 免疫応答を調節するための材料および方法
WO2013070565A1 (en) * 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
CA2854817C (en) * 2011-11-07 2022-08-16 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
CN104144945A (zh) * 2012-03-02 2014-11-12 埃博灵克斯股份有限公司 结合铜绿假单胞菌pcrv的单可变结构域抗体
US20150284450A1 (en) * 2012-11-06 2015-10-08 Medimmune, Llc Combination therapies using anti-pseudomonas psl and pcrv binding molecules
MX2015007575A (es) * 2012-12-13 2016-03-15 Univ Pennsylvania Construcciones de anticuerpos de adn y metodo para utilizarlas.
SG11201604719WA (en) * 2013-12-13 2016-07-28 Univ Pennsylvania Dna antibody constructs and method of using same
WO2015171504A1 (en) * 2014-05-05 2015-11-12 Medimmune, Llc Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療

Also Published As

Publication number Publication date
EA201892525A1 (ru) 2019-04-30
JP2023058497A (ja) 2023-04-25
MX2018013525A (es) 2019-06-10
KR20190025826A (ko) 2019-03-12
AU2017261374B2 (en) 2024-06-20
CN110072554A (zh) 2019-07-30
WO2017193101A1 (en) 2017-11-09
EP3452090A1 (en) 2019-03-13
CA3023094A1 (en) 2017-11-09
AU2017261374A1 (en) 2018-12-20
SG10202011016WA (en) 2020-12-30
AU2024203766A1 (en) 2024-06-27
US20190153076A1 (en) 2019-05-23
BR112018072716A2 (pt) 2019-02-19
JP2019520085A (ja) 2019-07-18
SG11201809778TA (en) 2018-12-28
EP3452090A4 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
KR20230093338A (ko) 슈도모나스 에루지노사에 대해 사용하기 위한 dna 항체 작제물
CN110402255A (zh) 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
AU2017238168A1 (en) DNA antibody constructs and method of using same
CN110088135A (zh) 抗cd20/抗cd3双特异性抗体和4-1bb(cd137)激动剂的组合疗法
TW201930353A (zh) 使用經靶向之ox40促效劑的組合療法
JP2009540828A (ja) Ilt3結合分子およびその使用
JP2023086734A (ja) Il-6及びcd126を標的とするdnaモノクローナル抗体
US20230322894A1 (en) Methods and compositions for treating glioblastoma
JP2023126321A (ja) ライム病に対する使用のためのdna抗体構築物
KR20220150274A (ko) Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
CA3162246A1 (en) Anti-muc1 compositions and methods of use
TWI819352B (zh) 包含il-12及抗fap抗體的融合蛋白及其用途
KR20220034807A (ko) Cd38에 대해 특이성을 갖는 항체 및 이의 용도
RU2813829C2 (ru) Конструкции днк-антител для применения против болезни лайма
KR20190114963A (ko) 에볼라 바이러스에 대한 사용을 위한 dna 항체 작제물
CN116744966A (zh) Dna编码的用于抵抗sars-cov-2的抗体

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal